Evolus, Inc. – LSE:0K16.L

Add to watchlist

$6.731

-4.20

-38.47%

Market open

Closed in about 6 hours

-7.52%

month

-7.52%

quarter

+10.28%

year

Market Cap	679.75M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-1.05

Revenue	219.00M
EBITDA	-37.75M
Income	-60.00M
Revenue Q/Q	42.21%
Revenue Y/Y	40.00%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	-17.24%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Evolus, Inc. (LSE:0K16.L): Profit margin
Jun 2023	49.34M	-18.14M	-36.76%
Sep 2023	49.32M	-16.92M	-34.31%
Dec 2023	60.99M	-11.83M	-19.4%
Mar 2024	59.33M	-13.10M	-22.09%

Evolus Financials Estimate

Q Y

Evolus, Inc. (LSE:0K16.L): Analyst Estimates
Mar 2024	59.33M	-13.10M	-22.09%
Sep 2025	132.55M	1.60M	1.21%
Oct 2025	91.2M	2.41M	2.64%
Dec 2025	99.8M	8.64M	8.66%

Analysts Price target
Financials & Ratios estimates

Evolus, Inc. (LSE:0K16.L): Debt to assets
Jun 2023	168983000	175.94M	104.12%
Sep 2023	167971000	187.33M	111.53%
Dec 2023	188998000	209.68M	110.95%
Mar 2024	226176000	207.73M	91.85%

Evolus, Inc. (LSE:0K16.L): Cash Flow
Jun 2023	-13.31M	-216K	23.82M
Sep 2023	-34.82M	-1.26M	21.11M
Dec 2023	813K	-361K	23.52M
Mar 2024	-10.61M	-797K	45.66M

Evolus alternative data

Evolus, Inc. (LSE:0K16.L): Employee count
Aug 2023	224
Sep 2023	215
Oct 2023	215
Nov 2023	215
Dec 2023	246
Jan 2024	246
Feb 2024	246
Mar 2024	273
Apr 2024	273
May 2024	273
Jun 2024	279
Jul 2024	279

Frequently Asked Questions (FAQ)

What's the price of Evolus stock today?

One share of Evolus stock can currently be purchased for approximately $6.73.
When is Evolus's next earnings date?

Unfortunately, Evolus's (0K16.L) next earnings date is currently unknown.
Does Evolus pay dividends?

No, Evolus does not pay dividends.
How much money does Evolus make?

Evolus has a market capitalization of 679.75M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 35.98% to 202.09M US dollars.
What is Evolus's stock symbol?

Evolus, Inc. is traded on the LSE under the ticker symbol "0K16.L".
What is Evolus's primary industry?

Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
How do i buy shares of Evolus?

Shares of Evolus can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Evolus have?

As Jul 2024, Evolus employs 279 workers, which is 2% more then previous quarter.
When Evolus went public?

Evolus, Inc. is publicly traded company for more then 7 years since IPO on 3 Aug 2018.
What is Evolus's official website?

The official website for Evolus is evolus.com.
Where are Evolus's headquarters?

Evolus is headquartered at 520 Newport Center Drive, Newport Beach, CA.
How can i contact Evolus?

Evolus's mailing address is 520 Newport Center Drive, Newport Beach, CA and company can be reached via phone at +94 92844555.

Evolus, Inc.

evolus.com

Exchange:

LSE

Full time employees:

322

Industry:

Medical - Pharmaceuticals

Sector:

Healthcare

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

+94 92844555

520 Newport Center Drive
Newport Beach, CA 92660

:
ISIN: US30052C1071
: